GENE ONLINE|News &
Opinion
Blog

2022-11-28|

Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan

by GeneOnline
Share To

NEW TAIPEI CITY, Taiwan, Nov. 28, 2022 /PRNewswire/ — Medeologix, a Taiwan MedTech CDMO company announces its successful acquisition of three premier medical device manufacturing companies to form an integrated full function service group. The newly formed Medeologix family of companies, with a combined footprint of 90,000 sq.ft, offers one-stop services from conceptual design to high-volume production.

The three Silicon Valley companies, Mediballoon, MedeonBio and Second Source Medical, along with Medeologix with a mass production facility in Taiwan, form the vertically integrated services from medical tubing extrusion, balloon forming, catheter processing, final assembly to packaging and logistic services. Together, they work seamlessly to support their clients from concepts to quality finished medical products for the MedTech industry.

MediBalloon, established in 2016, is an expert in extruding medical tubing and developing medical balloons in different shapes and sizes using various thermoplastic materials including Polyurethane, Polyethylene, Polyvinylidene fluoride (PVDF), Polybutylene terephthalate (PBT), Polyethylene terephthalate (PET), PEBAX, and Nylons. The customer base includes startups and major OEM giants who seek fast turn-around time for their standard and complex balloon designs and catheter tubing.

MedeonBio, established in 2012, specializes in single and multi-lumen catheter processes, including braiding, coil winding, lamination, thermal fusing, tipping, balloon bonding and pleating, as well as hydrophilic coating. These catheters are commonly used in minimally invasive procedures for cardiovascular, neurovascular, peripheral and structural heart diseases.

Second Source Medical, established in 2004, is an FDA registered contract manufacturer with full FDA QSR and cGMP compliant for Class II and Class III PMA products, providing rapid response of integrated design and manufacturing services from component, functional prototype, subassembly, process development, verification and validation leading to pilot and mass productions in support of successful clinical trial, regulatory approval and commercialization. In addition to its 2,000 sq.ft clean room, Second Source Medical also houses a yellow lab to handle UV light sensitive liquid mixing processes as well as a Silicone forming lab.

Medeologix family of companies are ISO 13485 certified. The alignment of quality systems among each company and within the entire group provides seamless transition from concept stage to production scale up without costly re-validation and production delay, thus assuring their clients the most efficient services. In addition, the in-house expertise provides regulatory submission services for 510K, PMA and MDR, as well as help startups incubate their projects with virtual offices and quality system setup; a true major source for MedTech outsourcing solutions.

About

Medeologix (www.Medeologix.com) with its headquarters in New Taipei City, Taiwan, is a MedTech CDMO group with development centers and manufacturing facilities located in California USA and Taiwan. It is founded with the goal of helping MedTech companies around the globe to go from concept to product launch to mass-production. Medeologix provides a suite of vertically integrated technology know-how and state-of-the-art engineering design and manufacturing capabilities to produce leading edge medical tubing, custom balloons, catheter and many other devices of the highest quality and greatest efficiency at extremely competitive total cost.  For more information, please send your inquiry to sales@Medeologix.com or call (408) 432-6388. 

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Bio4t2 announces first patient infused with CAR-T targeting solid tumors
2023-01-10
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
2023-01-10
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer
2023-01-10
LATEST
NDA for Biogen-Sage’s Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development
2023-02-07
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
2023-02-07
FDA Expands Approval For Takeda’s Takhzyro To Prevent Hereditary Angioedema Attacks
2023-02-06
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
2023-02-04
First Human Trial for Marburg Virus Vaccine Reports Success
2023-02-03
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
2023-02-03
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
2023-02-03
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!